Eton Pharmaceuticals (NASDAQ:ETON) Hits New 52-Week High – What’s Next?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $32.51 and last traded at $32.49, with a volume of 402805 shares traded. The stock had previously closed at $30.26.

Wall Street Analyst Weigh In

ETON has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Tuesday, April 21st. HC Wainwright upped their price target on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Craig Hallum upped their price target on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Finally, Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $41.00.

Eton Pharmaceuticals Trading Up 7.4%

The business has a fifty day simple moving average of $24.18 and a 200 day simple moving average of $19.22. The stock has a market cap of $889.90 million, a price-to-earnings ratio of -464.08 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The company had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. As a group, equities analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current year.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Cannell Capital LLC boosted its holdings in shares of Eton Pharmaceuticals by 17.3% during the third quarter. Cannell Capital LLC now owns 455,405 shares of the company’s stock worth $9,896,000 after purchasing an additional 67,230 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Eton Pharmaceuticals by 44.9% during the third quarter. JPMorgan Chase & Co. now owns 351,417 shares of the company’s stock worth $7,636,000 after purchasing an additional 108,837 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Eton Pharmaceuticals during the third quarter worth $1,922,000. Lumbard & Kellner LLC acquired a new stake in shares of Eton Pharmaceuticals during the third quarter worth $3,831,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Eton Pharmaceuticals during the third quarter worth $767,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.